阿托伐他汀对不稳定型心绞痛血脂及C反应蛋白的影响被引量：13

下载PDF

导出

摘要目的探讨阿托伐他汀对不稳定型心绞痛(UAP)患者血脂和C-反应蛋白(CRP)水平的影响。方法 80例UAP患者随机分为阿托伐他汀调脂治疗组(40例)和非调脂治疗组(40例),分别测定治疗前后甘油三酯(TG)、总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)及血清CRP的水平。结果治疗4周后,与非调脂治疗组相比,阿托伐他汀调脂治疗组患者血清CRP和TC、TG及LDL-C浓度显著降低(P均<0.05),而非调脂治疗组治疗前后差异无统计学意义(P>0.05)。结论 UAP患者早期应用阿托伐他汀能安全、有效地降低血脂和CRP,升高HDL-C。

作者王东生

机构地区通许县人民医院

出处《河南职工医学院学报》 2011年第2期164-165,共2页 Journal of Henan Medical College For Staff and Workers

关键词阿托伐他汀不稳定型心绞痛 C-反应蛋白血脂

分类号 R541.4 [医药卫生—心血管疾病]

引文网络
相关文献

参考文献6

1不稳定性心绞痛诊断和治疗建议[J].中华心血管病杂志,2000,28(6):409-412. 被引量：2696
2Koerig W.Inflammation and coronary heart disease:an overview[J].Cardiol Rev,2001,9:31-35. 被引量：1
3Rider PM.Clinical application of C-reactive protein for cardiovascular disease and prevention[J].Circulation,2003,107(3):363-369. 被引量：1
4Ray KK,Cannon CP.The potential relevance of the multiple lipidindependent pleiotropic effects of statins in the management of acute coronary syndromes[J].J Am Coll Cardiol,2005,46:1 425. 被引量：1
5郑幼兰,朱惠,黄庆标,林建峰.他汀类药物调脂作用研究进展[J].海峡药学,2002,14(6):3-5. 被引量：17
6曹国良,乔永芳,刘新兵,俞建华.辛伐他汀早期干预对非ST抬高型急性冠脉综合征细胞因子水平的影响[J].实用诊断与治疗杂志,2006,20(7):478-480. 被引量：40

二级参考文献25

1朱燕,李长龄,王银叶.血脂康对高脂家兔、鹌鹑模型的降脂作用[J].中国药学杂志,1995,30(11):656-660. 被引量：83
2Lennernas H,Fager G.Pharmacodynamics and pharmacodynamics of the HMG-CoA redu-etase inhibitors:similartites and differences,Clin Pharmacokinet 1997,32(5)∶403～423. 被引量：1
3Todd PA,Goa KL.Simvastatin,A review of its pharmacoiogical properties and therapeutic potential in hypercholesterolemia.Drugs 1990,40(4)∶583～607. 被引量：1
4Lea AP,Mc TD.Atorvastatin,Areview of its pharmacology and potential in the management of hyperlipidaemias.Drugs 1997,53(5)∶828～847. 被引量：1
5Kobayashi M,Ishida F,Takahashi T,et al.Preventive effect of MK-733(Simvastatin),an inhibitors of HMG-CoA reductase,on hypercholesterolemia and atherosclerosis induced by cholesterol feeding in rabbits.Japan J Pharmacol 1989,49∶125～133. 被引量：1
6Dart A,Jerums G,Nicholson G et al.A multicenter,double-blind,one-year study comparing safety and efficacy of atorvastatin versus simvastatin in patients with hypercholesterolemia.Am J Cardiol 1997,80(1)∶39～44. 被引量：1
7Laufs U,Fata VL.Plutzky J,et al.Upregulation of endothelial nitric oxide synthase by HMG-CoA reductase inhibitors.Circulation 1998,97∶1129～1133. 被引量：1
8Sakai M,Kobcri S,Marsumura T,et al.MHG-CoA reductase inhibitors suppress macrophage growth induced by oxidized low density lipoprotein.Atherosclerosis 1997,133∶51～59. 被引量：1
9Negre AP,Vliet AK,V anarick M,et al.Inhibition of proliferation of human smooth muscle cells by various HMG-CoA reductase inhibitors:comparison with other human cell types.Biochem Biophys Acta 1997,1345∶259～268. 被引量：1
10Rosenson RS,Tangney CC.Antiatherothrombotic properties of statins:implications for cardiovascular event reduction.JAMA 1998,279(20)∶1643～1650. 被引量：1